Published in Science Immunology · View the paper (DOI)
Researchers found that a combination of ruxolitinib and remdesivir can normalize the production of complement proteins in lung epithelial cells infected with SARS-CoV-2. This highlights a promising strategy to treat damaging inflammation during severe COVID-19.
Coverage from 2 institutions